TheraVectys SA is considering an initial public offering in Hong Kong, according to people familiar with the matter, a rare ...

ATLATL, one of China’s leading biotech incubators, is seeking to bridge East-West innovation and tap into China's rapidly ...

Most biotech firms will be forced to reevaluate foreign relationships and re-route supply chains, or hope for a federal ...

After a prolonged funding chill, investors say 2026 is shaping up for continued dealmaking and diversified bets beyond ...

Small and mid-cap biotech stocks entered 2025 like a compressed spring, and it finally snapped higher— here's why.

The performance metrics speak volumes. The iShares Biotechnology ETF (NASDAQ: IBB) has climbed 29.51% year to date through December 29, while the State Street SPDR S&P Biotech ETF (NASDAQ: XBI) has ...

Strive Asset Management has raised $750 million to pursue the strategy while Ramaswamy runs to be Ohio's governor Entrepreneur and politician Vivek Ramaswamy made much of his fortune founding ...

The sheer growth of small biotechs and mid‑sized pharma companies entering the field has reshaped expectations of Contract ...

After five years, Nido Biosciences has reached the end of the road, closing its doors after its lead neurological disease ...

Jarez Holz says 2026 will be a strong year for biotech stocks. The Mizuho analyst explained why in a recent CNBC interview.